ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Direct Indexing
    • Disruptive Technology
    • Energy Infrastructure
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Financial Literacy
    • Fixed Income
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Modern Alpha
    • Multifactor
    • Night Effect
    • Portfolio Strategies
    • Responsible Investing
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Disruptive Technology Channel
  2. Some Value At Hand in High Octane Healthcare ETF
Disruptive Technology Channel
Share

Some Value At Hand in High Octane Healthcare ETF

Tom LydonNov 18, 2021
2021-11-18

Healthcare innovators, including genomics companies, are rarely inexpensive in equity market terms. Often, rich multiples are simply the cost of admission that investors have to pay to access a high-growth parts of the healthcare sector.

However, there are times when some biotechnology and genomics stocks go on sale, confirming to investors that there are occasional values to be had in what’s typically considered a growth segment of the market.

While it’s a not a value fund in the typical sense, the ARK Genomic Revolution Multi-Sector Fund (ARKG A-) is home to some stocks that currently offer attractive valuations — a rarity in the genomics space.

Barron’s recently ran a screen for biotech stocks “with a market cap of over $5 billion that trade the farthest below their average analyst target prices as calculated by FactSet,” reports Josh Nathan-Kazis for the financial journal. “The four stocks that passed the screen—Fate Therapeutics (FATE), CRISPR Therapeutics (CRPS), Denali Therapeutics (DNLI), and Ultragenyx Pharmaceutical (RARE)—are developing some of the most cutting-edge technologies in biotech, and have garnered substantial excitement. Analysts see reasons for all four to gain.”

Fate Therapeutics is the sixth-largest member of the ARKG roster at a weight of 3.79%, as of Nov. 17. The company is a clinical-stage firm focusing on cancer treatments — often a hot corner of the biotechnology arena.

Fate “has seen its shares drop 39.5% this year. Its average analyst target price is $105.63, according to FactSet, implying a 99.2% gain over its recent price of $53.03,” according to Barron’s.

CRISPR Therapeutics is another ARKG member firm that made the Barron’s screen. That stock commands 2.72% of the fund’s weight. CRISPR specializes in gene editing therapy, a cutting-edge concept that ARKG features more exposure to than some competing funds. The stock is down 43.7% year-to-date and resides 84.5% below the consensus price target.

“At a $7 billion valuation [with] no products yet approved, we have to acknowledge that it is STILL a highly valued stock,” Evercore ISI analyst Liisa Bayko wrote in a note to clients earlier this month. “Still, with multiple programs entering the clinic, the potential upside is substantial. “If [proof of concept] works, this could open a floodgate of opportunities. We’re excited.”

For more news, information, and strategy, visit the Disruptive Technology Channel.

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X